Mo Khan of Open Orphan & Dr Andrew Catchpole of hVIVO discuss developing world's first Omicron human challenge model
Episode 773, Jun 30, 2022, 06:59 AM
Mo Khan CEO of Open Orphan #ORPH & Dr Andrew Catchpole, Chief Scientific Officer of hVIVO discuss developing the world's first Omicron human challenge model in collaboration with Vaxart Inc. to conduct a subsequent Omicron human challenge study in 2023 to test the efficacy of Vaxart's oral vaccine candidate, VXA-CoV2-1.
Mo Khan CEO of Open Orphan #ORPH & Dr Andrew Catchpole, Chief Scientific Officer of hVIVO discuss developing the world's first Omicron human challenge model in collaboration with Vaxart Inc. to conduct a subsequent Omicron human challenge study in 2023 to test the efficacy of Vaxart's oral vaccine candidate, VXA-CoV2-1.